Mechanism research of non-coding RNA in immune checkpoint inhibitors therapy

IF 4.5 2区医学 Q1 ONCOLOGY Cancer Science Pub Date : 2024-08-13 DOI:10.1111/cas.16309

Jie Bian, Rui Shao, Juan Li, Jing-Feng Zhu, Ai-Zhong Shao, Chao Liu, L. V. Lu, Hui-Wen Pan, Yi-Jun Shi, Na Fang

{"title":"Mechanism research of non-coding RNA in immune checkpoint inhibitors therapy","authors":"Jie Bian, Rui Shao, Juan Li, Jing-Feng Zhu, Ai-Zhong Shao, Chao Liu, L. V. Lu, Hui-Wen Pan, Yi-Jun Shi, Na Fang","doi":"10.1111/cas.16309","DOIUrl":null,"url":null,"abstract":"<p>Immune checkpoint inhibitor (ICI) therapies for tumors of different systems have attained significant achievements and have changed the current situation of tumor treatment due to their therapeutic characteristics of high specificity and low side effects. The immune checkpoint Programmed death 1/Programmed cell death-Ligand 1 (PD-1/PD-L1) axis exerts a vital role in the immune escape of tumor cells. As a result, it has become a key target for tumor immunotherapy. Therefore, to perfect research into potential regulatory factors for the PD-1/PD-L1 axis, in order to understand and illustrate tumor ICI therapy mechanisms, is a significant goal. Moreover, ncRNA has been verified to regulate the PD-1/PD-L1 axis in the tumor immune microenvironment to regulate tumor genesis and development. ncRNAs can improve or decrease the efficacy of ICI therapy by modulating PD-L1 expression. This review aimed to investigate the mechanisms of action of ncRNA in regulating the PD-1/PD-L1 axis in ICI therapy, to provide more efficient immunotherapy for tumors of different systems.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 11","pages":"3520-3531"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531961/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16309","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immune checkpoint inhibitor (ICI) therapies for tumors of different systems have attained significant achievements and have changed the current situation of tumor treatment due to their therapeutic characteristics of high specificity and low side effects. The immune checkpoint Programmed death 1/Programmed cell death-Ligand 1 (PD-1/PD-L1) axis exerts a vital role in the immune escape of tumor cells. As a result, it has become a key target for tumor immunotherapy. Therefore, to perfect research into potential regulatory factors for the PD-1/PD-L1 axis, in order to understand and illustrate tumor ICI therapy mechanisms, is a significant goal. Moreover, ncRNA has been verified to regulate the PD-1/PD-L1 axis in the tumor immune microenvironment to regulate tumor genesis and development. ncRNAs can improve or decrease the efficacy of ICI therapy by modulating PD-L1 expression. This review aimed to investigate the mechanisms of action of ncRNA in regulating the PD-1/PD-L1 axis in ICI therapy, to provide more efficient immunotherapy for tumors of different systems.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非编码 RNA 在免疫检查点抑制剂治疗中的机制研究。

针对不同系统肿瘤的免疫检查点抑制剂（ICI）疗法取得了重大成果，以其高特异性、低副作用的治疗特点改变了肿瘤治疗的现状。免疫检查点程序性死亡 1/程序性细胞死亡配体 1（PD-1/PD-L1）轴在肿瘤细胞的免疫逃逸中发挥着重要作用。因此，它已成为肿瘤免疫疗法的关键靶点。因此，完善对 PD-1/PD-L1 轴潜在调控因子的研究，以了解和阐明肿瘤 ICI 治疗机制是一个重要目标。此外，ncRNA已被证实可在肿瘤免疫微环境中调控PD-1/PD-L1轴，从而调控肿瘤的发生和发展。本综述旨在研究 ncRNA 在 ICI 治疗中调节 PD-1/PD-L1 轴的作用机制，为不同系统的肿瘤提供更有效的免疫治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Science 医学-肿瘤学

自引率

3.50%

发文量

406

审稿时长

2 months

期刊介绍： Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.

期刊最新文献

Issue Information In this issue Issue Information In this issue Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications